Norroy Bioscience to Showcase its Advancements with 11 Accepted Abstracts on Radiopharmaceuticals at EANM 2026

Norroy Bioscience to Showcase its Advancements with 11 Accepted Abstracts on Radiopharmaceuticals at EANM 2026 Norroy Bioscience announces today that a total of eleven abstracts featuring the latest data on its growing portfolio and pipelines will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM 26)—the world’s largest gathering of nuclear medicine professionals to be held in Vienna, Austria, from 17–21 October 2026. 

Norroy Bioscience’s abstracts for presentations include 8 Top-rated Oral Presentations and 3 e-Posters. The presentations will showcase expanding clinical and preclinical evidences across Norroy's radiopharmaceutical pipelines, including novel diagnostic and therapeutic agents for renal cancer, prostate cancer, small cell lung cancer, primary aldosteronism, hepatocellular carcinoma, and neuroendocrine neoplasms. Featured studies include an evaluation of ⁶⁸Ga-NYM096 PET/CT in patients with metastatic or recurrent clear cell renal cell carcinoma (ccRCC) compared with contrast-enhanced CT, as well as a head-to-head comparison of ¹⁸F-NYM124 and ¹⁸F-FDG PET/CT in diagnosing ccRCC. 8 Top Rated Oral Presentations.

· Diagnostic Accuracy of 68Ga-NYM096 PET/CT for Clear Cell Renal Cell Carcinoma: An imaging-histopathology correlation study

· Beyond Bosniak Classification: CA9-Targeted 68Ga-NYM096 PET/CT for Characterizing Cystic Renal Masses

· One-stop-shop imaging for VHL syndrome using 68Ga-NYM096 PET/CT · Diagnostic Performance of 18F-NYM124, a Novel Small-Molecule CAIX-Targeted Probe, in ccRCC: A Prospective Head-to-Head Comparison with 18F-FDG PET/CT 

· Initial Safety and Efficacy of 177Lu-NYM032 in Progressive mCRPC: A Phase I/II Study · First-in-Human Preliminary Study of Low-Dose [161Tb]Tb-NYM032, a PSMA-Targeted Radiopharmaceutical, in Patients with mCRPC

· A Novel ACP3-Targeted Radiotracer 68Ga/177Lu-NY129 for Molecular Imaging of Prostate Cancer 

· A Novel GPC3-Targeting Peptide for HCC Radiotheranostics: Preclinical Evaluation 3 E-Posters 

· 68Ga-NYM096 PET/CT in patients with metastatic or recurrent clear cell renal cell carcinoma: compared with contrast-enhanced CT 

· Preclinical Evaluation of 68Ga-NYM184, a Novel CXCR4-Targeted Radiotracer for PET Imaging 

· Preclinical Evaluation of NYM158, a Novel 177Lu-Labeled SSTR2 Antagonist for Aggressive Neuroendocrine Neoplasms and SCLC 

Visit Norroy Bioscience at Booth #ExpoX2-267 to explore opportunities for global collaboration involving innovative radiopharmaceuticals, radioligand therapies, automated radiopharmaceutical production, and integrated capabilities in R&D, clinical development, and manufacturing.